Previous 10 | Next 10 |
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022 Phase 1 trial in glaucoma expected to commence in first quarter of 2023 Acquired corneal gene therapy program; Phase 1/2a data expected in fourth quarter of 2023 N...
BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - ...
Graybug Vision press release (NASDAQ:GRAY): FY GAAP EPS of -$1.69 misses by $0.06. As of December 31, 2021, the company’s cash, cash equivalents, and short-term investments totaled $63.7 million, compared to $95.0 million as of December 31, 2020. For further details see: Graybug ...
BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today provided an update on recent corporate developments and reported financial...
The following slide deck was published by Graybug Vision, Inc. in conjunction with this event. For further details see: Graybug Vision (GRAY) Presents At Annual SVB Leerink Global Health Conference
BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medica...
BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will e...
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive...
Graybug Vision (NASDAQ:GRAY): Q3 GAAP EPS of -$0.38 misses by $0.01. Revenue of $0M Press Release For further details see: Graybug Vision EPS misses by $0.01
BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments ...
News, Short Squeeze, Breakout and More Instantly...
Graybug Vision Inc. Company Name:
GRAY Stock Symbol:
NASDAQ Market:
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 - Phase 2b results ...
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its tradin...
Toronto, Ontario--(Newsfile Corp. - March 2, 2023) - Graycliff Exploration Limited (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) (the " Company " or " Graycliff ") is pleased to announce that it has acquired the Lunge Project ("Lunge") located on the prolific Canadian Shield in the Sudbury Basin...